Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nat Genet. 2021 Jan;53(1):11-15. doi: 10.1038/s41588-020-00752-4. Epub 2021 Jan 4.
In multiple cancer types, high tumor mutational burden (TMB) is associated with longer survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with survival outside of the immunotherapy context is poorly understood. We analyzed 10,233 patients (80% non-ICI-treated, 20% ICI-treated) with 17 cancer types before/without ICI treatment or after ICI treatment. In non-ICI-treated patients, higher TMB (higher percentile within cancer type) was not associated with better prognosis; in fact, in many cancer types, higher TMB was associated with poorer survival, in contrast to ICI-treated patients in whom higher TMB was associated with longer survival.
在多种癌症类型中，高肿瘤突变负担（TMB）与免疫检查点抑制剂（ICI）治疗后的生存时间延长相关。TMB 与免疫治疗环境之外的生存之间的关联尚未得到很好的理解。我们分析了 10233 名患有 17 种癌症的患者（80%未经 ICI 治疗，20%经 ICI 治疗），这些患者在 ICI 治疗前/未经 ICI 治疗或 ICI 治疗后进行了分析。在未经 ICI 治疗的患者中，较高的 TMB（在癌症类型内的较高百分位）与更好的预后无关；实际上，在许多癌症类型中，较高的 TMB 与较差的生存相关，与接受 ICI 治疗的患者形成对比，后者较高的 TMB 与更长的生存时间相关。
